Le Lézard
Classified in: Health, Science and technology
Subjects: TDS, FVT

Avirmax Inc. to Make Scientific Presentations at ASGCT in Baltimore


HAYWARD, Calif., April 15, 2024 /PRNewswire/ -- Avirmax Inc., will make two scientific presentations at the upcoming American Society of Gene and Cell Therapy (ASGCT) annual meeting in Baltimore between May 7th and 11th, 2024. In addition, Avirmax will have an exhibitor booth #818 to showcase the latest progress and data package. ASGCT is the largest international society dedicated to understanding, development, and application of gene and cell therapy.

Title: Macular retina-targeting AAV capsid identified through multi-species screening in mice, rabbits, pigs, and monkeys
Presenter: Li Ou, Ph.D.
Session title: AAV Capsid Engineering: Multilevel Approaches for Enhanced AAV Delivery
Presentation type: Oral Presentation
Date and Time: Friday, May 10, 3:45pm - 4:00pm

This presentation focuses on Avirmax's lead candidate ABI-110 for wet AMD and PCV using a proprietary novel capsid AAV2.N54. AAV2.N54 was developed through capsid engineering and showed significantly improved tropism to the macular retina over wildtype serotypes and AAV2.7m8 in mice, rabbits, pigs, and non-human primates. Avirmax Biopharma has completed cGMP manufacturing of ABI-110 using VSafTM  rAAV Production Platform with Sf-rhabdovirus free Sf9 cells and presently prepares regulatory submission for clinical investigations.

Title: Comprehensive Head-to-Head Comparisons Demonstrated Key Advantages of The Sf9 System Over HEK293 in rAAV Manufacturing
Presenter: Li Ou, Ph.D.
Session title: AAV Vectors - Product Development Manufacturing and Approval Considerations
Presentation type: Poster Presentation
Date and Time: Friday, May 10, 12:00 pm

This presentation focuses on the systematic comparison between AAV vectors manufactured by the traditional HEK293 plasmid transfection system and the Sf9/baculoviral infection system. As shown in the publication in Molecular Therapy from Avirmax, the Sf9 system has advantages in yields, full capsid ratio, aggregation, purity, and potency over traditional HEK293 systems.

About Avirmax Inc.
Avirmax Inc. is a San Francisco-based company specializing in developing rAAV-mediated therapeutics for ocular diseases using its AAV engineering technologies and Sf9-based AAV manufacturing platform. Visit us at avirmax.com for more information.

References

Liu S, Li J, Peraramelli S, Luo N, Chen A, Dai M, Liu F, Yu Y, Leib RD, Li Y, Lin K, Huynh D, Li S, Ou L. Systematic comparison of rAAV vectors manufactured using large-scale suspension cultures of Sf9 and HEK293 cells. Mol Ther. 2023 Nov 20:S1525-0016(23)00623-8.

Contact

Please contact
June Song, Associate Director for Operations
Email: [email protected]
Tel: +1-510-641-0201

Address

25503 Whitesell Street
Hayward 94545 CA
USA

SOURCE Avirmax


These press releases may also interest you

at 18:05
The ODP Corporation ("ODP," or the "Company") , a leading provider of business services, products and digital workplace technology solutions to businesses and consumers, announced today that its executive vice president and chief financial officer,...

at 18:00
Trip.com Group Limited ("Trip.com Group" or the "Company"), a leading one-stop travel service provider of accommodation reservation, transportation ticketing, packaged tours, and corporate travel management, today announced its unaudited financial...

at 17:55
City of Hope®, one of the largest cancer research and treatment organizations in the United States, has been awarded $5.4 million from the California Institute for Regenerative Medicine (CIRM) to build and fund a stem cell research laboratory on its...

at 17:30
Tuya Inc. ("Tuya" or the "Company") , a global leading cloud platform service provider, today announced its unaudited financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Highlights Total revenue was US61.7...

at 17:00
Zepp Health Corporation ("Zepp" or the "Company") today reported revenues of US$39.8 million; a basic and diluted net loss per share of US$0.06; and a basic and diluted net loss per ADS of US$0.23 for the first quarter ended March 31, 2024;...

at 17:00
Yalla Group Limited ("Yalla" or the "Company") , the largest Middle East and North Africa (MENA)-based online social networking and gaming company, today announced its unaudited financial results for the first quarter ended March 31, 2024. First...



News published on and distributed by: